Optimization of an orthotopic murine model of head and neck squamous cell carcinoma in fully immunocompetent mice - Role of toll-like-receptor 4 expressed on host cells

Cancer Letters

Volumn 317, Issue 2, 2012, Pages 199-206

  Vahle, Anne Kristin ^a   Kerem, Alexander ^a   Öztürk, Ender ^a   Bankfalvi, Agnes ^a   Lang, Stephan ^a   Brandau, Sven ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Head and neck squamous cell carcinoma; Immunocompetent murine model; Orthotopic murine model; Toll like receptor; Tumor immune system interaction; Tumor stroma interaction

Indexed keywords

TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C3H MOUSE; CACHEXIA; CANCER CONTROL; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HOST CELL; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; CACHEXIA; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; RECEPTORS, CHEMOKINE; TIME FACTORS; TOLL-LIKE RECEPTOR 4; TUMOR BURDEN;

MURINAE; MUS;

EID: 84856614244     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.027     Document Type: Article

References (21)

1. Petrelli N.J., Winer E.P., Brahmer J., Dubey S., Smith S., Thomas C., Vahdat L.T., Obel J., Vogelzang N., Markman M., Sweetenham J.W., Pfister D., Kris M.G., Schuchter L.M., Sawaya R., Raghavan D., Ganz P.A., Kramer B. Clinical cancer advances 2009: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J. Clin. Oncol. 2009, 27:6052-6069.
2. Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert. Opin. Biol. Ther. 2005, 5:1085-1093.
3. Strauss L., Bergmann C., Gooding W., Johnson J.T., Whiteside T.L. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2007, 13:6301-6311.
4. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 2006, 16:3-15.
5. Kim S. Animal models of cancer in the head and neck region. Clin. Exp. Otorhinolaryngol. 2009, 2:55-60.
6. Sano D., Myers J.N. Xenograft models of head and neck cancers. Head Neck Oncol. 2009, 1:32.
7. Lu S.L., Herrington H., Wang X.J. Mouse models for human head and neck squamous cell carcinomas. Head Neck 2006, 28:945-954.
8. Huang B., Zhao J., Unkeless J.C., Feng Z.H., Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008, 27:218-224.
9. O'Malley B.W., Cope K.A., Johnson C.S., Schwartz M.R. A new immunocompetent murine model for oral cancer. Arch. Otolaryngol. Head Neck Surg. 1997, 123:20-24.
10. Cannon T.Y., Guttridge D., Dahlman J., George J.R., Lai V., Shores C., Buzkova P., Couch M.E. The effect of altered Toll-like receptor 4 signaling on cancer cachexia. Arch. Otolaryngol. Head Neck Surg. 2007, 133:1263-1269.
11. Poltorak A., He X., Smirnova I., Liu M.Y., Van H.C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
12. Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., Fenton M.J., Tracey K.J., Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179.
13. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., Mayer L., Unkeless J.C., Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005, 65:5009-5014.
14. Olive P.L., Chaplin D.J., Durand R.E. Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br. J. Cancer 1985, 52:739-746.
15. Szczepanski M.J., Czystowska M., Szajnik M., Harasymczuk M., Boyiadzis M., Kruk-Zagajewska A., Szyfter W., Zeromski J., Whiteside T.L. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009, 69:3105-3113.
16. Kim S., Takahashi H., Lin W.W., Descargues P., Grivennikov S., Kim Y., Luo J.L., Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
17. Conforti R., Ma Y., Morel Y., Paturel C., Terme M., Viaud S., Ryffel B., Ferrantini M., Uppaluri R., Schreiber R., Combadiere C., Chaput N., Andre F., Kroemer G., Zitvogel L. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 2010, 70:490-500.
18. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F.J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J.P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., Andre F., Delaloge S., Tursz T., Kroemer G., Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
19. Bergmann C., Bachmann H.S., Bankfalvi A., Lotfi R., Putter C., Wild C.A., Schuler P.J., Greve J., Hoffmann T.K., Lang S., Scherag A., Lehnerdt G.F. Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J. Trans. Med. 2011, 9:139.
20. Cabanillas R., Secades P., Rodrigo J.P., Astudillo A., Suarez C., Chiara M.D. [Orthotopic murine model of head and neck squamous cell carcinoma]. Acta Otorrinolaringol. Esp. 2005, 56:89-95.
21. Trellakis S., Bruderek K., Dumitru C.A., Gholaman H., Gu X., Bankfalvi A., Scherag A., Hutte J., Dominas N., Lehnerdt G.F., Hoffmann T.K., Lang S., Brandau S. Polymorphonuclear granulocytes in human head and neck cancer: Enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int. J. Cancer 2011, 129:2183-2193.